Right ventricular failure (RVF) after left ventricular assist device (LVAD) implantation is a major cause of morbidity and mortality. This review offers pediatric-focused guidance on perioperative RV management, emphasizing pathophysiology, hemodynamics, and targeted interventions to optimize outcomes.
In this multicenter retrospective study of 150 pediatric patients supported with the Impella device, 89.3% achieved positive clinical outcomes despite a 28% adverse event rate. Findings suggest a potential role for Impella in managing refractory advanced heart failure in children, particularly those with cardiomyopathy, transplant graft dysfunction, or congenital heart disease.
Abstract We report the largest pediatric multicenter experience with Impella pump use and peripheral veno-arterial extracorporeal membrane oxygenation (VA-ECMO) support. Utilizing the Advanced Cardiac Therapies Improving Outcomes Network (ACTION) collaborative
“Characteristics and Outcomes of Patients Supported with Impella Percutaneous VAD Device at Pediatric Institutions: Action Collaborative Experience” SEBASTIAN TUME, ET AL Download the Abstract
The Jarvik 2015 VAD, the first and currently only continuous-flow VAD specifically designed for small children, is being assessed in the Pump for Kids, Infants, and Neonates (PumpKIN) trial. Inclusion
“Compassionate” Cases of the Jarvik 2015 VAD Read More »
